Express Scripts’ (ESRX) “Buy” Rating Reaffirmed at Cowen

Cowen reissued their buy rating on shares of Express Scripts (NASDAQ:ESRX) in a report released on Friday. Cowen currently has a $88.00 price target on the stock.

ESRX has been the subject of a number of other research reports. Royal Bank of Canada set a $101.00 price objective on shares of Express Scripts and gave the company a buy rating in a report on Thursday. ValuEngine upgraded shares of Express Scripts from a hold rating to a buy rating in a report on Monday, September 17th. Robert W. Baird lowered shares of Express Scripts from an outperform rating to a neutral rating and set a $81.00 price objective for the company. in a report on Friday, July 20th. BidaskClub upgraded shares of Express Scripts from a buy rating to a strong-buy rating in a report on Friday, October 12th. Finally, William Blair upgraded shares of Express Scripts from a market perform rating to an outperform rating in a report on Wednesday, August 1st. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $88.73.

Shares of ESRX opened at $96.74 on Friday. Express Scripts has a 1-year low of $59.17 and a 1-year high of $98.98. The stock has a market cap of $54.55 billion, a P/E ratio of 13.63, a P/E/G ratio of 1.22 and a beta of 0.89. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.77 and a quick ratio of 0.59.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.01. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. The company had revenue of $25.56 billion during the quarter, compared to analyst estimates of $25.11 billion. During the same quarter last year, the business posted $2.51 EPS. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. Research analysts forecast that Express Scripts will post 9.08 EPS for the current fiscal year.

In other news, insider Christine Houston sold 12,898 shares of the business’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $85.00, for a total value of $1,096,330.00. Following the completion of the sale, the insider now owns 110,908 shares in the company, valued at approximately $9,427,180. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.79% of the company’s stock.

Several large investors have recently bought and sold shares of the company. TRUE Private Wealth Advisors purchased a new position in shares of Express Scripts in the 3rd quarter worth approximately $115,000. Palo Capital Inc. purchased a new position in shares of Express Scripts in the 3rd quarter worth approximately $124,000. Landaas & Co. WI ADV purchased a new position in shares of Express Scripts in the 2nd quarter worth approximately $102,000. Kaizen Advisory LLC grew its position in shares of Express Scripts by 147.6% in the 2nd quarter. Kaizen Advisory LLC now owns 1,342 shares of the company’s stock worth $104,000 after buying an additional 800 shares during the last quarter. Finally, Adviser Investments LLC grew its position in shares of Express Scripts by 321.9% in the 2nd quarter. Adviser Investments LLC now owns 1,481 shares of the company’s stock worth $114,000 after buying an additional 1,130 shares during the last quarter. Institutional investors and hedge funds own 84.74% of the company’s stock.

Express Scripts Company Profile

Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.

Further Reading: Discover Your Risk Tolerance

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply